The HVTN 124 Protocol Safety Review Team has reviewed the cumulative safety data for the first 12 participants in Part A, and concluded that enrollment can begin in HVTN 124 Part B.
Learn more about the HVTN 124 trial
News
Recruitment of WHV leadership team complete
WHV hired Dr. Shixia Wang as Scientific Director and Mr. Edward Gibson as Business Manager.
Learn more about Our Team
WHV hires Dr. Yegor Voronin as its Chief Operating Officer
WHV hired Dr. Yegor Voronin to manage the day-to-day operation of the company and to develop the strategy for development of its PDPHV preventive HIV vaccine candidate. Dr. Voronin previously served as the Senior Science Officer at the Global HIV Vaccine Enterprise in New York. He brings over 15 years of HIV research and vaccine development expertise. Dr. Voronin holds a Ph.D. from the West Virginia University and did his postdoctoral fellow training in the laboratories of Dr. Michael Emerman and Dr. Julie Overbaugh at the Fred Hutchinson Cancer Research Center, Seattle.
HVTN 124 trial enrolls its first volunteer
The HVTN 124 clinical trial testing WHV’s polyvalent DNA-prime/protein-boost vaccine opened for recruitment on March 16, 2018. The first volunteer was enrolled into the trial on April 19, 2018.
Learn more about our Vaccine Candidate
Learn more about the HVTN 124 trial
WHV licenses HIV vaccine candidate from UMMS
WHV founder, Mr. Weibo Li, signed a licensing agreement with the University of Massachusetts Medical School to advance the development of the preventive HIV vaccine created in the laboratory of Dr. Shan Lu.
Learn more about our Founder.
Learn more about our Vaccine Candidate.
